DNLI

Denali Therapeutics Inc. Common Stock (DNLI)

Stock · NASDAQ · Health Care

$24as of 8/28/2026

Active signals

No technical signal is currently active for this symbol.

Support level
$19.15
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Denali Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • DNLI
    Denali Therapeutics Inc. Common Stock
    $24
    ▼ 2.72%
    Market cap $3.67BP/E
  • ADPT
    Adaptive Biotechnologies Corporation Common Stock
    $25.19
    ▼ 4.73%
    Market cap $3.70BP/E
    $12$26.87
  • RLAY
    Relay Therapeutics Inc. Common Stock
    $18.78
    ▼ 3.30%
    Market cap $3.60BP/E
    $3.5$21.27
  • BEAM
    Beam Therapeutics Inc. Common Stock
    $29.31
    ▼ 3.84%
    Market cap $2.67BP/E
    $16.02$38.26
  • CRSP
    CRISPR Therapeutics AG Common Shares
    $57.69
    ▼ 2.84%
    Market cap $4.78BP/E
    $44.12$78.48
  • KOD
    Kodiak Sciences Inc Common Stock
    $37.77
    ▼ 3.45%
    Market cap $2.49BP/E
    $8.29$47.84
  • COAG
    Hemab Therapeutics Holdings Inc. Common Stock
    $44.77
    ▼ 9.55%
    Market cap $2.10BP/E
    $23$55.42

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held
140.66M
Total value held
$2.47B
Institutional holders
263
Top holders this quarter
  • Unknown13.03M
  • Unknown12.07M
  • Unknown8.52M
  • Unknown7.01M
  • Unknown6.27M
  • Unknown6.15M
  • Unknown4.58M
  • Unknown4.43M
  • Unknown4.41M
  • Unknown3.73M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.